Recent data indicates that phentermine, often referred to as a weight loss pill, has been the most reported drug for side effects among obesity treatments prescribed in Korea.Such data was confirmed through a joint study conducted by Kyung Hee University's School of Pharmacy and Ajou University's Sc
AstraZeneca Korea's lung cancer drug Tagrisso (osimertinib) has passed the Drug Reimbursement Evaluation Committee, taking a step closer to expanded coverage for first-line lung cancer treatment.The Health Insurance Review and Assessment Service (HIRA) held the 10th committee meeting on Thursday and
Aptose Biosciences, the U.S. partner of Hanmi Pharm in the development of HM43239, an acute myeloid leukemia (AML) treatment candidate containing tuspetinib, has announced the successful completion of a $3 million investment from Hanmi in the form of common shares in the company.According to Aptose,
Korea United Pharm said it has signed a five-year supply and distribution agreement with MCQ, a Thai-based pharmaceutical company specializing in drug distribution, for Levotics CR Tab., a mucoactive drug.Levotics CR Tab. is an incrementally modified drug (IMD) that improves compliance and convenien
Some Korean biopharmaceutical companies, including LG Chem, Hanmi Pharmaceutical, and Daewoong Bio, are considering introducing the continuous manufacturing (CM) process, attracting the industry’s attention.Unlike the existing “batch-type” production, continuous manufacturing (CM) is a method of man
ABL Bio said Thursday it signed a non-exclusive license agreement to use Synaffix's antibody-drug conjugate (ADC) platform technology to develop up to three ADCs using its antibodies. The agreement includes an upfront payment, tiered milestones, and royalties in exchange for non-exclusive rights. St
Daewoong Pharmaceutical said Thursday that its botulinum toxin product Nabota (Juveau in the U.S.) was patented as a neurotoxin composition for treating headaches through its U.S. partner, AEON Biopharma, with exclusive rights until 2041.The patent obtained from the U.S. Patent and Trademark Office
FutureChem said it has received the final report for the U.S. phase 1 clinical trial of FC705, a prostate cancer treatment candidate.The University of Maryland Medical Center and five other centers conducted the phase 1 trial in the U.S.According to the results, all participating patients who receiv
Oncology experts celebrated the joint reimbursement of Opdivo together with its PD-L1 IHC 28-8 PharmDx companion diagnostic (CDx) platform for first-line treatment and diagnosis of advanced and metastatic gastric cancer in Korea.However, they noted diagnosis platforms need work to improve treatment
Ybrain, a company specializing in mental health therapeutics, said on Wednesday that a clinical trial conducted in the U.S. using its depression electroceutical, MINDD STIM, showed efficacy in improving immediate depression symptoms.Depressed patients have difficulty interpreting other people's emot
SK biopharmaceuticals and Korea Cancer Center Hospital (KCCH) said Monday they have signed a memorandum of understanding (MOU) to develop radiopharmaceutical therapies (RPT).The two will collaborate on new drug research, clinical development, and the establishment of actinium-225 (Ac-225) production
EuBiologics together with the International Vaccine Institute (IVI), said on Tuesday that it signed a technology transfer agreement with DEK Vaccines to enable the domestic production and supply of the oral cholera vaccine (OCV) in Ghana.Recently, cholera has been spreading around the world due to c
The socioeconomic benefits of prolonged progression-free survival (PFS) by using Enhertu (ingredient: trastuzumab deruxtecan) in the second-line treatment of HER2-positive metastatic breast cancer patients in Korea amount to approximately 260 billion won ($196.3 million), a study showed.In Korea, En
SK bioscience said it has voluntarily withdrawn its application for a conditional marketing authorization (CMA) license to the European Medicines Agency (EMA) for SKYCovion (Korean name: SKYCovione), the country's first locally-develop Covid-19 vaccine.The withdrawal comes after one year and one mon
Pfizer Korea's Ngenla (active ingredient: somatrogon) will be covered by health insurance for the treatment of growth hormone deficiency in children aged three or older, starting in September.Reimbursement eligibility extends to pediatric patients aged three or older with growth hormone secretion di
HK inno.N said on Monday that its K-CAB (ingredient: tegoprazan), a treatment for gastroesophageal reflux disease (GERD), has been officially launched in Singapore. HK inno.N held a symposium at Conrad Centennial Singapore to commemorate the launch of the drug inviting gastroenterologists in Singapo
Vivozon Pharmaceutical’s Chairman Lee Doo-hyun, whose company is developing non-narcotic painkiller opiranserin (VVZ-149), has issued a strongly worded statement to its shareholders and employees.Last Wednesday, the company posted a statement on its website last month in the name of Chairman Lee."Fo
Daewoong Pharmaceutical said on Sunday that it applied to the Ministry of Food and Drug Safety (MFDS) for a long-term phase 3 clinical trial to demonstrate the long-term safety and efficacy of Envlo (ingredient: enavogliflozin) 0.3-milligram tablets in combination with gemigliptin and metformin, for
Numeco, an affiliate of the botulinum toxin (BTX) maker Medytox, said the Ministry of Food and Drug Safety has approved Newlux, a next-generation BTX product.Newlux, Numeco's first BTX preparation, is a next-generation toxin preparation in a freeze-dried powder formulation.The BTX is characterized b
AVEO Pharmaceuticals, a subsidiary of LG Chem, has completed the U.S. phase 2 clinical trial of ficlatuzumab, a head and neck cancer candidate, and published the results in an international journal.As the LG Group has recently shown its commitment to developing new drugs, LG Chem's plans are drawing